DRHCI interventions significantly reduce travel time for Veterans living in rural areas, improve clinical outcomes via remote early diagnosis and treatment, and provide affordable and accessible health care options. “This center positions VA at the forefront of digital health technology with the mission of providing best-in-class preventative care for Veterans,” said Director of DRHCI Dr. Lindsay Riegler. “It allows us to systematically evaluate innovative digital health and remote patient monitoring solutions so that VHA can make informed, validated health care decisions.”
DRHCI is one of five National Centers for Innovation to Impact (NCI2I) within VHA Innovation Ecosystem and the first to partner with VHA's Office of Connected Care. This collaboration promotes cooperation between VA, academia, and the private and public sectors to address urgent health care issues and connect VHA strategic priorities with scalable solutions.
 During this month’s edition of "The Exchange," leaders from across Veterans Health Administration (VHA) came together to discuss advancements in cancer care for Veterans. The event highlighted significant progress and ongoing efforts to enhance cancer treatment and screening through advanced manufacturing, telehealth services, and innovative medical technologies.
Innovative Cancer Screening Programs
Chris Moore, leader of the VHA’s colorectal cancer screening initiative Mailed FIT, opened the conversation by highlighting the urgent need to increase screening rates among Veterans. Moore emphasized that colorectal cancer is the second leading cause of cancer deaths among Veterans but is preventable with early detection. He discussed Mailed FIT: his program that intends to promote at-home annual testing through telehealth modalities, aiming to improve screening rates and early detection.
“We’re not screening enough for colon cancer,” Moore said. “If we screen people early enough, we can get them the proper care they need for a preventable condition.” Moore shared Mailed FIT’s approach to at-home stool tests and tele-screening to address common misconceptions and logistical challenges faced by Veterans, aiming to enhance cancer care accessibility.
Enhancing Oncology Care through Telehealth
Dr. Vida Passero, Chief Medical Officer for the National TeleOncology service, emphasized the importance of expanding telehealth services to improve access to oncology care for Veterans. Dr. Passero discussed her leadership in building subspecialty oncology teams and implementing initiatives like the Close to Me Cancer Care Service. Dr. Passero discussed how, through Close to Me, the VA Pittsburgh Multidisciplinary Virtual Cancer Care Network has established TeleOncology clinics in rural areas, ensuring that Veterans receive timely and effective treatment.
Also representing the Close to Me program, Dr. Jenna Shields, the National Oncology Program Pharmacy Manager, highlighted her dedication to improving cancer care for Veterans. “Some medications don’t travel well, or aren’t stable long enough,” said Dr. Shields. “So, the difficulty is operationalizing the process of getting cancer care to those in rural areas.”
Advanced Manufacturing in Cancer Care
Brian Strzelecki, Deputy Director of Production for VHA's Office of Advanced Manufacturing (OAM), continued the discussion by emphasizing the transformative role of advanced manufacturing technologies in cancer care. Strzelecki, with his background in mechanical engineering and 3D printing, discussed how personalized medical devices are revolutionizing treatment.
“Our OAM team is on the mission to build manufacturing capabilities sin VA to provide health care solutions for our Veterans,” said Strzelecki. “We sought to make things more personalized.”
Following Strzelecki, Lorelei Gorr, also representing OAM, spoke in her capacity as a Clinical Engineer at VA Ventures. She discussed her contributions as the Product Lead for the VHA DEAN Radiotherapy Bolus, a 510(k) cleared Class 2 medical device used in radiation therapy treatments. Gorr shared insights on how her background in biomedical engineering has enabled her to streamline the procurement and deployment of medical equipment, enhancing the delivery of personalized radiotherapy for Veterans with cancer.
Personalized Prescription Tailoring
Dr. Rona Margaret Relova, a VHA Innovation Ecosystem Senior Innovation Fellow and Research Health Scientist, shared insights on the VHA IE fellowship programs. As part of the 2024 Fellowship cohort, Dr. Relova co-directs a clinical pharmacogenomics (PGx) program at VA Palo Alto Health Care System. PGx translates evidence-based findings to a novel approach in medical care, enabling individualized prescription of medications based on patient’s genes.
“Pharmacogenomics allows us to take out the guess work of prescription medicine and give patients the proper, most effective, dosages from the start,” said Dr. Relova. “We can find out how much chemotherapy will work for a patient, or if it will work at all, by conducting a PGx test before prescribing a dosage.”
Specifically, Dr. Relova’s fellowship project aims to eliminate wait times for providers to receive their patients’ PGx results. PGx test results are obtained at a non-VA facility and must be manually transferred into the VA database. Dr. Relova is working to automate this process to provide better cancer care for Veterans, faster.
*Recording is only accessible on the VA network
|